"post-menopause is defined as amenorrhoea ≥1 year, or if uncertain or the uterus absent then the patient is considered post-menopausal if >50 years old 4"
"post-menopause is defined as amenorrhoea ≥1 year, or if uncertain or the uterus absent then the patient is considered post-menopausal if >50 years old 4"
"The Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US) forms the ultrasound component of the Ovarian-Adnexal Reporting and Data System (O-RADS). This article reflects the v2022 update 4."
"The Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US) forms the ultrasound component of the Ovarian-Adnexal Reporting and Data System (O-RADS). This article reflects the v2022 update 4."
"The Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US) forms the ultrasound component of the Ovarian-Adnexal Reporting and Data System (O-RADS). This article reflects the v2022 update 4."
"For MRI, see the Ovarian-Adnexal Reporting and Data System MRI (O-RADS MRI)."
"These recommendations have been published to guide the management of "average-risk patients without acute symptoms" who demonstrate adnexal lesions. Individual case management may be modified based on professional judgement, regardless of the O-RADS ultrasound recommendations 1."
"A meta-analysis published in 2023 5 has shown that the actual rates of malignancy for O-RADS scores 2 to 5 matched the predicted risk levels."
"For risk stratification, the O-RADS US system uses five categories from normal (1) to high risk of malignancy (5). An O-RADS US 0 (zero) category is used for an incomplete evaluation 4."
"For risk stratification, the O-RADS US system uses five categories from normal (1) to high risk of malignancy (5). An O-RADS US 0 (zero) category is used for an incomplete evaluation 4."
"For risk stratification, the O-RADS US system uses five categories from normal (1) to high risk of malignancy (5). An O-RADS US 0 (zero) category is used for an incomplete evaluation 4."
"For risk stratification, the O-RADS US system uses five categories from normal (1) to high risk of malignancy (5). An O-RADS US 0 (zero) category is used for an incomplete evaluation 4."
"O-RADS US 0"
"O-RADS US 0"
"O-RADS US 1"
"O-RADS US 1"
"O-RADS US 2"
"O-RADS US 2"
"premenopausal: O-RADS US 1 finding"
"premenopausal: O-RADS US 1 finding"
"non-simple but smooth unilocular cyst OR smooth bilocular cyst ≤3 cm"
"non-simple but smooth unilocular cyst OR smooth bilocular cyst 3-10 cm"
"O-RADS US 3"
"O-RADS US 3"
"O-RADS US 4"
"O-RADS US 4"
"O-RADS US 5"
"O-RADS US 5"
"O-RADS US does not apply in the setting of pelvic inflammatory disease, ectopic pregnancy, ovarian torsion, and non-ovarian/non-tubal lesions 4"
"O-RADS US does not apply in the setting of pelvic inflammatory disease, ectopic pregnancy, ovarian torsion, and non-ovarian/non-tubal lesions 4"
"when multiple lesions are present, each should be assigned a separate O-RADS US score 4"
"when multiple lesions are present, each should be assigned a separate O-RADS US score 4"
"O-RADS was developed and published in 2018 by an international multidisciplinary committee, comprising clinicians and researchers from the fields of radiology, gynaecology, pathology, and gynaecologic oncology, and sponsored by the American College of Radiology (ACR). It was originally designed for sonographic evaluation, and in 2020 the system was extended to include MRI evaluation. The O-RADS MRI was an evolution from the AdnexMR Scoring System published in 2012. An update (v2022) to the O-RADS assessment system was published by the ACR in 2022 4."
"O-RADS was developed and published in 2018 by an international multidisciplinary committee, comprising clinicians and researchers from the fields of radiology, gynaecology, pathology, and gynaecologic oncology, and sponsored by the American College of Radiology (ACR). It was originally designed for sonographic evaluation, and in 2020 the system was extended to include MRI evaluation. The O-RADS MRI was an evolution from the AdnexMR Scoring System published in 2012. An update (v2022) to the O-RADS assessment system was published by the ACR in 2022 4."
"O-RADS was developed and published in 2018 by an international multidisciplinary committee, comprising clinicians and researchers from the fields of radiology, gynaecology, pathology, and gynaecologic oncology, and sponsored by the American College of Radiology (ACR). It was originally designed for sonographic evaluation, and in 2020 the system was extended to include MRI evaluation. The O-RADS MRI was an evolution from the AdnexMR Scoring System published in 2012. An update (v2022) to the O-RADS assessment system was published by the ACR in 2022 4."
"Ovarian-Adnexal Reporting and Data System Magnetic Resonance Imaging (O-RADS MRI)"
"Gynaecologic imaging reporting and data system (GI-RADS)"
"RADS (Reporting and Data Systems)"
"O-RADS US - American College of Radiology"
"O-RADS US - American College of Radiology"
"O-RADS US Calculator and Report Generator - Rad At Hand"
"O-RADS US Calculator and Report Generator - Rad At Hand"
"O-RADS US 0"
"O-RADS US 1"
"O-RADS US 2"
"O-RADS US 3"
"O-RADS US 4"
"O-RADS US 5"
"Colour scoring (CS) indicator"
"O-RADS US does not apply in the setting of pelvic inflammatory disease, ectopic pregnancy, ovarian torsion, and non-ovarian/non-tubal lesions 4"
"Ovarian-Adnexal Reporting and Data System Magnetic Resonance Imaging (O-RADS MRI)"
"Gynaecologic imaging reporting and data system (GI-RADS)"
"O-RADS US - American College of Radiology"
"O-RADS US Calculator and Report Generator - Rad At Hand"
Expected headings
"Classification"
"O-RADS US 0"
"O-RADS US 1"
"O-RADS US 2"
"O-RADS US 3"
"O-RADS US 4"
"O-RADS US 5"
"Colour scoring (CS) indicator"
"External links"